Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,231 Mln
Revenue (TTM)
$140 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2
Industry P/E
--
EV/EBITDA
-7
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$11.8
EPS
$-0.8
Face value
--
Shares outstanding
101,856,245
CFO
$-383.69 Mln
EBITDA
$-1,097.33 Mln
Net Profit
$-1,195.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Beam Therapeutics (BEAM)
| -12.6 | -14.9 | -12.6 | 24.0 | -7.5 | -21.3 | -- |
|
BSE Sensex*
| -15.3 | -11.8 | -15.8 | -5.7 | 6.7 | 7.5 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Beam Therapeutics (BEAM)
| 11.8 | -8.8 | -30.4 | -50.9 | -2.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Beam Therapeutics (BEAM)
|
24.2 | 2,230.7 | 139.7 | -80.0 | -69.6 | -8.1 | -- | 2.0 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include... Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Address: 238 Main Street, Cambridge, MA, United States, 02142 Read more
CEO & Director
Mr. John M. Evans M.B.A.
CEO & Director
Mr. John M. Evans M.B.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Beam Therapeutics Inc (BEAM) is $24.22 (NASDAQ) as of 01-Apr-2026 16:17 EDT. Beam Therapeutics Inc (BEAM) has given a return of -7.52% in the last 3 years.
Since, TTM earnings of Beam Therapeutics Inc (BEAM) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-36.36
|
2.35
|
|
2024
|
-5.45
|
2.80
|
|
2023
|
-16.99
|
2.29
|
|
2022
|
-9.58
|
3.77
|
|
2021
|
-14.62
|
6.55
|
The 52-week high and low of Beam Therapeutics Inc (BEAM) are Rs 36.44 and Rs 13.53 as of 02-Apr-2026.
Beam Therapeutics Inc (BEAM) has a market capitalisation of $ 2,231 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Beam Therapeutics Inc (BEAM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.39
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.